A Quantitative analysis of adverse events and "overwarning" in drug labeling

Archives of Internal Medicine

Volumn 171, Issue 10, 2011, Pages 944-946

  Duke, Jon ^a   Friedlin, Jeff ^a   Ryan, Patrick ^b  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b University of North Carolina   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR;

ADVERSE DRUG REACTION; DRUG APPROVAL; DRUG LABELING; DRUG MECHANISM; DRUG SAFETY; FOOD AND DRUG ADMINISTRATION; HUMAN; LETTER; MEDICINE; PHYSICIAN; PRACTICE GUIDELINE; PRESCRIPTION; PRIORITY JOURNAL; PRODUCT SAFETY; QUANTITATIVE ANALYSIS; STRUCTURED PRODUCT LABEL; TABLET FORMULATION; UNSPECIFIED SIDE EFFECT;

ADVERSE DRUG REACTION REPORTING SYSTEMS; DRUG LABELING; EVALUATION STUDIES AS TOPIC; HUMANS; PRODUCT SURVEILLANCE, POSTMARKETING; TOTAL QUALITY MANAGEMENT; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 79957577277     PISSN: 00039926     EISSN: 15383679     Source Type: Journal    
DOI: 10.1001/archinternmed.2011.182     Document Type: Letter

References (9)

1. Woosley RL, Woosley RL. Drug labeling revisions-guaranteed to fail? JAMA. 2000;284(23):3047-3049.
2. Avorn J, Shrank W. Highlights and a hidden hazard-the FDA's new labeling regulations. N Engl J Med. 2006;354(23):2409-2411.
3. Food and Drug Administration, HHS. Requirements on content and format of labeling for human prescription drug and biological products. Final rule. Fed Regist. 2006;71(15):3921-3997.
4. US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research, Center for Biologics Evaluation and Research. Guidance for Industry: Adverse Reactions Section of Labeling for Human Prescription Drug and Biological Products-Content and Format. Rockville, MD: Food and Drug Administration; 2006.
5. US National Library of Medicine. About DailyMed. http://dailymed.nlm.nih.gov/dailymed/about.cfm. Accessed December 17, 2009.
6. Schadow G. Structured product labeling improves detection of drugintolerance issues. J Am Med Inform Assoc. 2009;16(2):211-219.
7. Duke JD, Friedlin J. ADESSA: A Real-Time Decision Support Service for Delivery of Semantically Coded Adverse Drug Event Data. AMIA Annu Symp Proc. 2010;2010:177-181.
8. US National Library of Medicine. 2008AB National Drug File-Reference Terminology Source Information. 2009. http://www.nlm.nih.gov/research/umls/sourcereleasedocs/2008AB/NDFRT/attributes.html. Accessed November 14, 2009.
9. Center for Drug Evaluation and Research. Drugs@FDA Data Files. http://www.fda.gov/Drugs/InformationOnDrugs/ucm079750.htm. Accessed February 9, 2010.